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The role of Histamine H3 receptors (H3Rs) in memory, and the prospective of H3R
antagonists in pharmacological control of neurodegenerative disorders, e.g., Alzheimer
disease (AD) is well-accepted. For that reason, the procognitive effects of the H3R
antagonist DL77 on cognitive impairments induced with MK801 were tested in an
inhibitory passive avoidance paradigm (PAP) and novel object recognition (NOR) task in
adult male rats, using donepezil (DOZ) as a standard drug. Acute systemic pretreatment
with DL77 (2.5, 5, and 10 mg/kg, i.p.) significantly ameliorated memory deficits induced
with MK801 in PAP (all P < 0.05, n = 7). The ameliorative effect of most promising
dose of DL77 (5 mg/kg, i.p.) was reversed when rats were co-injected with the H3R
agonist R-(α)-methylhistamine (RAMH, 10 mg/kg, i.p.) (p = 0.701 for MK801-amnesic
group vs. MK801+DL77+RAMH group, n = 6). In the NOR paradigm, DL77 (5 mg/kg,
i.p.) counteracted long-term memory (LTM) deficits induced with MK801 (P < 0.05,
n = 6–8), and the DL77-provided effect was similar to that of DOZ (p = 0.788, n = 6–8),
and was reversed when rats were co-injected with RAMH (10 mg/kg, i.p.) (p = 0.877,
n = 6, as compared to the (MK801)-amnesic group). However, DL77 (5 mg/kg, i.p.)
did not alter short-term memory (STM) impairment in NOR test (p = 0.772, n = 6–8, as
compared to (MK801)-amnesic group). Moreover, DL77 (5 mg/kg) failed to modify anxiety
and locomotor behaviors of animals innate to elevated-plus maze (EPM) (p = 0.67 for
percentage of time spent exploring the open arms, p = 0.52 for number of entries
into the open arms, p = 0.76 for percentage of entries into the open arms, and
p = 0.73 number of closed arm entries as compared to saline-treated groups, all
n = 6), demonstrating that the procognitive effects observed in PAP or NOR tests were
unconnected to alterations in emotions or in natural locomotion of tested animals. These
results signify the potential involvement of H3Rs in modulating neurotransmitters related
to neurodegenerative disorders, e.g., AD.
Keywords: histamine H3 receptor, antagonist, learning and memory, Alzheimer’s disease, neurodegeneration,
passive avoidance paradigm, novel object recognition, behavioral research
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INTRODUCTION
Alzheimer’s disease (AD) is a life long-lasting brain disorder that
is considered by its cognitive deficits, memory impairment, and
dementia (Khunnawutmanotham et al., 2016; Shaik et al., 2016).
Following a recent report, around 36 million people worldwide
were diagnosed with dementia in recent years, and the number
is estimated to significantly increase by the double every two
decades, ultimately leading to more than 100 million people
with AD after four decades (Khunnawutmanotham et al., 2016).
The pathogenesis of AD is still complex, though several theories
have been established. The multifaceted pathophysiological
alterations include deficient cholinergic neurotransmission,
malfunctioning metabolic status of β-amyloid protein,
irregularities of numerous central neurotransmitters including
glutamate, norepinephrine, serotonin and dopamine, and the
contribution of neuroinflammation and high oxidative stress
to the progression of AD (Doraiswamy, 2002; Khan et al.,
2015; Sadek et al., 2016a). Brain histamine is an established
neurotransmitter in the central nervous system (CNS) (Arrang
et al., 1983, 1985, 1987a,b, 1988, 2007; Schwartz et al., 1986),
exerting its biological activities through interaction with four
histamine receptor (HR) subtypes (H1-H4R) that belong to the
family of G-protein coupled receptors (Schneider and Seifert,
2009; Panula et al., 2015). H1R and H2R are present in the brain
and periphery, whereas H4Rs are predominately expressed in
mast cells and leukocytes (Schneider and Seifert, 2009; Panula
et al., 2015). Contrary, H3Rs are abundant in the CNS (Arrang
et al., 1983, 1985, 1987a,b, 1988, 2007; Panula et al., 2015).
Moreover, H3Rs acting as auto-receptors in the CNS are coupled
to Gαi/o-proteins and are capable of controlling the synthesis
and release of histamine (Arrang et al., 1983, 1985, 1987a,b,
1988, 2007). Furthermore, H3Rs operating as hetero-receptors
located on non-histaminergic neurons in different brain regions
can also moderate the release of other neurotransmitters
including acetylcholine, glutamate, GABA, norepinephrine,
serotonin, dopamine (Brown et al., 2001, 2013). Previous
preclinical experiments have proposed H3R antagonists to be of
characteristic feature by their possible memory-enhancing effects
(Panula et al., 1998, 2015; Panula and Nuutinen, 2011; Sadek
and Stark, 2015; Sadek et al., 2016b). Accordingly, several H3R
antagonists improved cognitive deficits induced with ketamine
and MK801 in numerous animal models (Browman et al., 2004),
suggesting that these H3R antagonists may also be effective in
neurodegenerative disorders, e.g., AD (Witkin and Nelson, 2004;
Bardgett et al., 2010; Charlier et al., 2013; Sadek and Stark, 2015;
Sadek et al., 2016b). Among a wide range of H3R antagonists
investigated so far, H3R antagonists ABT-239 and A-431404
were found to ameliorate cognitive deficits induced by ketamine
and MK-801 in rodents, demonstrating enhanced procognitive
effects of these compounds compared to standard drugs, e.g.,
Abbreviations: AD, Alzheimer disease; H3Rs, histamine H3 receptors; RAMH,
R-(α)-methyl-histamine; DOZ, donepezil; MK801, dizocilpine; PAP, passive
avoidance paradigm; STL, step-through latency; NOR, novel object recognition;
STM, short-term memory; LTM, long-term memory; EPM, elevated plus maze;
p.o., per oral; i.p., intraperitoneal.
DOZ (Brown et al., 2013). Therefore, the central H3Rs embodies
an attractive target for the development of novel H3R antagonists
with the prospective therapeutic future in neurodegenerative
disorders (Yokoyama et al., 1993; Yokoyama, 2001; Harada et al.,
2004; Witkin and Nelson, 2004; Uma Devi et al., 2010; Bhowmik
et al., 2012, 2014; Sadek and Stark, 2015; Sadek et al., 2016b).
Regardless of the abovementioned experimental observations
for the role for H3Rs in the modulation of memory deficits and
related behaviors, targeting H3Rs in the CNS is not commonly
proposed as a future strategy to treat AD.
In the current study and as a continuation of our
research efforts, the procognitive effects of the non-
imidazole H3R antagonist, namely DL77 [1-(3-(4-tert-
pentylphenoxy)propyl)piperidine dihydrogenoxalate], with
high in vitro selectivity to human H3R, high antagonist affinity
in the subnanomolar concentration range and a pK i-value of
8.03, and high H3R antagonist in vivo potency with an ED50
value of 2.1 ± 0.2 mg/kg, per oral (p.o.) (Łazewska et al., 2006)
has been explored on its procognitive effects on memory deficits
induced with MK801 in PAP and NOR paradigms in adult male
rats applying DOZ as a reference drug. Moreover, the effects of
DL77 on anxiety and locomotor behaviors in EPM was assessed,
since anxiety and locomotion could influence the performance
of rats in PAP or NOR. Furthermore, the abrogative effects of the
histamine H3R agonist RAMH on the memory-enhancing effects
provided with DL77 in PAP and NOR paradigms were examined.
The non-imidazole H3R antagonist DL77 was selected for testing
in the current studies as it in an earlier study proved to exhibit
(5–15 mg/kg, i.p.) anticonvulsant properties and procognitive
effects on acquisition, consolidation and retrieval in the same
animal species (Sadek et al., 2016c). Also, a previous study
showed a promising effects of DL77 (3–30 mg/kg, i.p.) on alcohol
intake and preference in adult C57BL/6 mice (Bahi et al., 2015).
EXPERIMENTAL PROCEDURES
Animals
Male Wistar rats (inbred of Central Animal Facility of the UAE
University, aged 6–8 weeks) of body weight 180–220 g were used
for the study. The animals were retained in an air-conditioned
animal facility room with controlled temperature (24± 2◦C) and
humidity (55 ± 15%) under a 12 h light/dark cycle, and were
provided free access to food and water. Experiments were carried
out between 9:00 and 13:00 h, and all procedures were approved
by the Institutional Animal Ethics Committee of College of
Medicine and Health Sciences/United Arab Emirates University
(A30-13). All efforts were made to minimize animal suffering,
to reduce the number of animals used. Also, all behavioral
studies were conducted in a blinded fashion and by the same
experimenter.
Drugs
R-(α)-methylhistamine dihydrochloride (RAMH), donepezil
hydrochloride (DOZ), and MK801 hydrogen maleate were
purchased from Sigma-Aldrich (St Louis, Missouri, USA). The
H3R antagonist 1-(3-(4-tert-pentylphenoxy)propyl)piperidine
dihydrogenoxalate (DL77, 2.5, 5, 10, mg/kg) was synthesized by
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us in the Department of Technology and Biotechnology of Drugs
(Kraków, Poland) as described previously (Meier et al., 2001;
Łazewska et al., 2006). All drugs were dissolved in isotonic saline
and injected intraperitoneal (i.p.) at a volume of 1 ml/kg, and all
doses were expressed in terms of the free base.
Behavioral Tests
Inhibitory PAP Test
Male adult Wistar rats were tested in a two compartment step-
through passive avoidance apparatus (Step-through Cage, 7550,
Ugo Basile, Comerio, Italy) as described previously (Izquierdo
et al., 1999; Bernaerts et al., 2004; da Silva et al., 2009; Goshadrou
et al., 2013; Khan et al., 2015; Sadek et al., 2016a,c; Alachkar
et al., 2017; Sultan et al., 2017), with minor modifications. The
test was conducted in an automatically operated commercial
passive avoidance apparatus as previously described (Khan et al.,
2015; Sadek et al., 2016a,c; Alachkar et al., 2017). The experiment
consisted of two trials (training and testing) separated by a
24 h interval. Each rat in the first trial was placed in the white
compartment (facing the auto guillotine door) and after a 30-
s habituation period the door was raised automatically. The
rat was given a 60 s cut-off time to step-through to the dark
compartment. Rats that failed to move within this time period
were excluded from the test session on the following day. Once
the rat moved into the dark compartment, the sliding door was
lowered and a scrambled foot shock (0.4mA, 20Hz, 8.3ms) was
delivered to the grid floor for a duration of 3 s. The power of
the delivered foots-hock was designated following confirming
the sensitivity threshold that yields the minimal vocalization and
jumping responses in tested rats. The rat was removed from the
dark chamber directly after receiving the foot-shock, returned to
its home cage, and both compartments were cleaned. The animals
were trained for 3 consecutive days; in which they were injected
with saline i.p. 30–45min before each training session, with the
only modification that the cut-off latency was put at 300 s to
move to the dark compartment without delivery of scrambled
foot-shock (Khan et al., 2015; Sadek et al., 2016a,c). Rats that
did not move into the dark compartment during the training,
despite the practices carried out during training sessions, were
excluded from the current test. For each separate experiment,
9–11 animals of the same age and weight average were trained
on the step-through latency (STL) paradigm. Approximately 2–4
rats failed to demonstrate enhanced performance in a cut-off
time of 60 s. In the current series of behavioral experiments, a
group of 7 animals was used for each STL task conducted for the
PAP. In the test session, animals were turned amnesic with acute
systemic injection of MK801 (0.1 mg/kg, i.p.) 30–45min prior to
test session, and the animals were allowed to move to the dark
compartment for a maximum period of 300 s. In this test session,
the STL time for each rat to enter the dark compartment in 300 s
was measured.
Dose regimen
Six groups of seven rats each were used, and were pretreated
with Saline+Saline, MK801+Saline, MK801+DL77 (2.5, 5, and
10mg/kg, i.p.), orMK801+DOZ (1mg/kg, i.p.) 30–45min before
the test session, and the procognitive effects DL77 (2.5, 5, and 10
mg/kg, i.p.) on amnesia induced with acute systemic injection
of MK801 (0.1 mg/kg, i.p.) was investigated by determining
the STLs to move into the dark compartment. In an additional
experiment, a single group of seven rats received two injections;
the first injection contained the most effective dose of DL77
and was administered 30–45min before the PAP test, and the
second injection contained RAMH (10 mg/kg, i.p.) which was
administered 15–20min prior PAP test. The CNS penetrant H3R
agonist RAMH was injected 15–20min before the start of test
conduction to ensure its presence in the CNS, as RAMH shows
fast metabolism (Krause et al., 2001). Doses of DL77, DOZ, and
RAMH were chosen according to previously published results in
the same species of rodents (Orsetti et al., 2001, 2002; Khan et al.,
2015; Sadek et al., 2016a,c) (Figures 1, 2).
NOR Test
Recognition memory was assessed in a novel object recognition
(NOR) test as previously described (Ennaceur and Delacour,
1988; Izquierdo et al., 1999; de Lima et al., 2005; Karasawa et al.,
2008; Alachkar et al., 2017). The experiments were conducted in
a black open field box (50 × 35 ×50 cm), and the experimental
procedure included two sessions of habituation of 1 h interval,
whereby the animals were provided 3min time to explore the
apparatus. On the test day and after a 3min exploration of the
apparatus, two novel objects were introduced in two corners
(∼30 cm apart from each other). The objects (9× 5× 9 cm) used
in this study were wood blocks and existed in different shape and
color, but were of the same size. They appeared devoid of natural
FIGURE 1 | Effects of DL77 on MK801-induced memory deficits in an
inhibitory PAP in rats. Gray columns represent the mean STLs measured
during the training trial before the delivery of the foot-shock (pre-shock
latencies) and black columns the mean STLs measured during the retention
test (test latencies). Rats were injected with DL77 (2.5, 5, or 10mg/kg, i.p.) or
donepezil (DOZ, 1mg/kg, i.p.) 30min before the test session. $P < 0.001 for
mean STLs vs the value of the (saline)-treated group. **P < 0.001 for mean
STLs vs. the value of the (MK801)-treated group. #P < 0.05 for mean STLs
vs. the value of MK801+DOZ-treated group. Data are expressed as mean ±
SEM (n = 7).
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FIGURE 2 | Effect of vehicle, DL77, and RAMH on MK801-induced deficit in
an inhibitory PAP in rats. Gray columns represent the mean STLs measured
during the training trial before the delivery of the foot-shock (pre-shock
latencies) and black columns the mean STLs measured during the retention
test (test latencies). Rats were injected with DL77 (5 mg/kg, i.p.), RAMH, or a
combination of RAMH (10 mg/kg)+DL77 (5 mg/kg) 15min (RAMH) or 30min
(DL77) before the test session. $P < 0.001 for mean STLs vs. the value of the
(Saline)-treated group. **P < 0.001 for mean STLs vs. the value of the
(MK801)-treated group. Data are expressed as mean ± SEM (n = 7).
significance for the animals and had never been linked with
reinforcement. They were adequately heavy to be not displaced
by the tested rats. The experimental session consisted of two trials
T1 and T2, each lasting for 3min. In T1, rats were exposed to
two identical objects, and those exploring the objects for less than
10 s during T1 were excluded from the tests. In T2, performed
120min (for STM) or 24 h (for LTM) later, rats were exposed to
two objects, one of which was a duplicate of familiar object in
order to exclude olfactory traits, and another novel object. The
role (familiar or novel object) as well as the relative position of
the two objects were counterbalanced and arbitrarily permuted
during T2. The principle measure was the time spent by the
rat for exploring objects during both trials, namely T1 and T2.
The test box as well as all used objects were thoroughly cleaned
with 70% (volume/volume; v/v) alcoholic solution. All sessions of
NOR test were executed during the light phase (8:00–12:00 a.m.).
In order to detect procognitive effects of test compound, MK801
and test compound were dissolved in isotonic saline and injected
i.p. at a volume of 1 ml/kg 30–45min. following T1. The control
groups received an equivalent volume of saline injection. The
choice of doses and pretreatment times for each compound was
decided according to the results of most promising dose in PAP
and was derived from previously reported procognitive studies
(Bernaerts et al., 2004; da Silva et al., 2009; Goshadrou et al., 2013;
Khan et al., 2015; Sadek et al., 2016c; Alachkar et al., 2017; Sultan
et al., 2017).
Dose regimen
Six groups of six to eight rats each were used for the detection
of a procognitive effect in STM. The groups were injected with
Saline, MK801, MK801+DL77 (5 mg/kg, i.p.), MK801+DL77(5
mg/kg)+RAMH (10 mg/kg, i.p.), MK801+DOZ (1 mg/kg,
i.p.), or MK801+RAMH (10 mg/kg, i.p.) 30–45min before T2,
respectively, and the counteracting effects of DL77 on cognitive
deficits induced with MK801 were assessed by measuring the
time spent by the rat in exploring objects in both trials T1
and T2 for STM (Figure 3). In an additional experiment,
the procognitive effect of DL77 on MK801-induced memory
impairments was confirmed by abrogative study in which the
respective promising dose (5 mg/kg, i.p.) of DL77 and RAMH (10
mg/kg, i.p.) were co-administered to a separate group of six rats
30–45min prior to T2 and 24 h after T1. The latter experiment
was carried out to confirm the procognitive effect for LTM,
whereas control groups received comparable saline injections
(Figure 4). Doses of MK801, RAMH, and DOZ were chosen
according to previous experimental protocols of NOR (Bernaerts
et al., 2004; de Lima et al., 2005; da Silva et al., 2009; Goshadrou
et al., 2013; Khan et al., 2015; Sadek et al., 2016c; Alachkar et al.,
2017; Sultan et al., 2017).
EPM Test
Anxiety-like behaviors were evaluated in an EPM as previously
described (Jiang et al., 2016; Alachkar et al., 2017). The EPM
apparatus consisted of several parts including one central part (8
× 8 cm), two opposing open and closed arms (30 × 8 cm), and
nontransparent walls (30 cm in height). Between every session,
both the plat form and the wall were thoroughly cleaned using
10% alcoholic spray. Animals were placed individually in the
center arena of the maze (50 cm above the floor) facing an
open arm, and test sessions took place in the light phase (9:00–
12:00 a.m.). The amount of time spent with head and forepaws on
the open arms and closed arms of the maze as well as the number
of entries into each arm was manually scored for a session of
5min. The maze was thoroughly cleaned between sessions using
a tissue dampened with 70% (volume/volume; v/v) alcohol to
remove the odor after each rat was tested. The total number
of entries into the closed arms is usually used as an index of
locomotor activity in the test.
Dose regimen
Rats were divided into two groups of six rats each. One group
received saline injection i.p. 30–45min before the test and
test group received the H3R antagonist DL77 (5 mg/kg, i.p.)
for testing its modulating effects on anxiety and locomotion
(Figure 5).
Statistical Analysis
IBM R© SPSS Statistics R© version 24 software (IBM Middle
East, Dubai, United Arab Emirates) was used for all statistical
comparisons. The results of NOR were expressed as the means
and standard errors (SEM) of the exploratory time spent by
the rat exploring both objects in T1 and T2. The results of
the EPM test were expressed as the means and SEM of the
percentage time spent on open arms, number of entries into
the open arms, the percentage of entries into the open arms,
and number of entries into closed arms. Results of NOR and
EPM were analyzed by using a two-way analysis of variance
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FIGURE 3 | Effects of DL77 on MK801-induced STM cognitive deficits in NOR
paradigm in rats. Following training session T1, DL77 (5 mg/kg) or DOZ (1
mg/kg) was administrated i.p., followed 30min later by i.p. administration of
MK801 at a dose of 0.1 mg/kg. The test session T2 was performed 120min
(STM) after the training session T1. Results are calculated as individual
percentage of time spent exploring familiar (white columns) and novel (black
columns) objects. Data represent mean ± SEM (n = 6). **P < 0.001 vs.
respective familiar object. #P < 0.05 vs. MK801-treated group.
(ANOVA). When relevant post-hoc comparisons were performed
with Bonferroni’s test in case of a significant main effect. STLs
observed in PAP test were expressed as means and SEM.
Because of the arbitrary cutoff latency used, the results were
evaluated by using nonparametric Kruskal–Wallis ANOVA, and
the differences between groups were estimated by individual
Mann–Whitney U-tests. The criterion for statistical significance
was set at P-value of <0.05.
RESULTS
Memory-Enhancing Effects of H3R
Antagonist DL77 and Standard Drug DOZ
on Memory Deficits Induced with MK801 in
PAP Task
The effect of acute systemic injection of DL77 at three different
doses, namely 2.5, 5, and 10 mg/kg, and DOZ (1 mg/kg) on
memory deficits induced with MK801 in an inhibitory PAP test
in rats are shown in Figure 1. Statistical analysis of observed
results indicated that acute systemic pretreatment with the three
doses of DL77, and DOZ (1 mg/kg) prior to retention test
exhibited a significant memory-enhancing effect on STLs [H(5)
= 28.29; P < 0.001; Figure 1]. As shown following pairwise
comparisons, MK801 (0.1 mg/kg) decreased STL time when
compared to the (saline)-treated control group with (U = 28.00,
P < 0.05). Moreover, DL77 tested in three different doses (2.5,
5, and 10 mg/kg) showed significant improving effect on STLs
time when compared to (MK801)-treated group with (all P <
0.05). However, pretreatment with DL77 (5 mg/kg, i.p.) was
found to be not significantly different from (Saline)-treated
control rats (U = 38.50, p = 0.073) (Figure 1). Furthermore,
DL77 (5 mg/kg) showed signicantly higher improving effects on
FIGURE 4 | Effects of DL77 on MK801-induced LTM cognitive deficits in NOR
paradigm in rats. Following training session T1, DL77 (5 mg/kg) or DOZ (1
mg/kg) was administrated i.p., followed 30min later by i.p. injection of MK801
at a dose of 0.1 mg/kg. The test session T2 was performed 24 h (LTM) after
the training session T1. Results are calculated as individual percentage of time
spent exploring familiar (white columns) and novel (black columns) objects.
Data represent mean ±SEM (n = 6). **P < 0.001 vs. respective familiar object.
#P < 0.05 vs. MK801-treated group.
STL when compared with the DOZ(1mg)-provided memory-
enhancing efects with (U = 5.00, P < 0.05) (Figure 1).
Abrogative Effects of RAMH on the
Memory Improvement Provided with DL77
in MK801-Induced Deficits in PAP Task
For this experiment, a group of seven animals was injected with
the most promising dose of DL77 (5 mg/kg, i.p.) 30–45min prior
to test, and also adminstered with the H3R agonist RAMH (10
mg/kg, i.p.) 15min before the test session (Figure 2). As shown
in Figure 2, statistical analysis revealed that this factor had a
significant effect on the STL time [H(5) = 31.32; P < 0.001].
Moreover, pairwise comparisons indicated that acute systemic
pretreatment with DL77 (5 mg/kg, i.p.) enhanced STL time when
compared to the (MK801)-amnesic group with (U = 49.00;
P < 0.05). Interestingly, the improvmemnt of observed STL
time provided with DL77 was abrogated following acute co-
injection of RAMH (U = 49.00; p = 0.701: MK801-amnesic
group vs. MK801+DL77+RAMH group, Figure 2). Noteably,
acute systemic administration of RAMH (10 mg/kg, i.p.) alone
failed to affect the observed STL time inMK801-amnesic group as
well as in Saline group with no significant differences (U = 30.50;
p= 0.442) and (U = 20.50; p= 0.620), respectively (Figure 2).
Modulating Effects of H3R Antagonist
DL77 and DOZ on the STM Deficits
Induced with MK801 in NOR Task
The results observed for the total time exploring both objects
during T1 and T2 were not significantly different when
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comparing groups pretreated with saline and those injected
with MK801 (Table 1). The latter experimental observation is
substantial to exclude any confounding factors, e.g., that the
post-training treatment with the amnesic compound MK801 in
the first experiment did not modify sensorimotor considerations
such as locomotor activity and motivations of tested animals.
Furthermore, statistical results revealed that no significant
differences were present in exploratory times between the two
identical objects during T1 for each respective experimental
group of animals (Table 1). The observed results, also, showed
that acute systemic pretreatment with DL77 (5 mg/kg, i.p.) and
standard drug DOZ (1 mg/kg, i.p.) significantly counteracted
time spent exploring objects in T2 with [F(3, 20) = 13.76;
P < 0.001] when injected 30–45min after T1 (Figure 3). As
revealed by conducted post hoc analyses, MK801 (0.1 mg/kg, i.p.)
decreasedmemory toward the novel object in T2 when compared
to the (saline)-treated group with [F(1, 10) = 140.96; P < 0.001],
and DOZ (1 mg/kg, i.p.) significantly counteracted this memory
deficit in STM in T2 when compared to (MK801)-amnesic
group [F(1, 10) = 7.02; P < 0.05)]. Contrary, acute systemic
administration of DL77 (5 mg/kg, i.p.) did not counteract the
decreased STMwhen compared to (MK801)-amnesic group with
[F(1, 10) = 0.08; p= 0.772].
Modulating Effects of H3R Antagonist
DL77 and DOZ on the LTM Deficits Induced
with MK801 in NOR Task
The results showed that H3R antagonist DL77 (5 mg/kg, i.p.)
and standard drug DOZ (1 mg/kg, i.p.) when injected 30–
45min before T2 exhibited a significant counteracting effect
on time spent exploring objects in T2 with [F(5, 30) = 2.67;
P < 0.05] (Figure 4). Moreover, subsequent post-hoc analyses
revealed that MK801 (0.1 mg/kg, i.p.) decreased memory for
the novel object in T2 when compared to the (MK801)-amnesic
FIGURE 5 | Effects of acute systemic administration of DL77 on exploratory behavior in EPM. DL77 (5 mg/kg) did not alter the percentage of time spent on the open
arms of the EPM (A), increase the number of entries into the open arms (B) and the percentage of entries into the open arms (C). Acute systemic pretreatment with
the H3R antagonist/inverse agonist DL77 (5 mg/kg, i.p.) did not affect the number of closed arm entries (D). Data are expressed as mean ± SEM (n = 6).
TABLE 1 | Effects of DL77 on MK801-induced total exploratory time spent with both objects during training and test session in NOR in rats.
Group Time exploring objects (s)
n Training session STM Test session STM Training session LTM Test session LTM
Saline 6 37.50 ± 3.2 41.83 ± 2.67 36.67 ± 2.93 38.17 ± 3.86
MK801 8 36.00 ± 2.73 42.25 ± 1.57 23.63 ± 2.73 28.88 ± 2.32
MK801 + DL77(5 mg/kg) 8 24.88 ± 2.73 28.17 ± 3.57 23.50 ± 1.71 23.63 ± 2.73
MK801+DL77(5 mg/kg)+RAMH(10 mg/kg) 6 ND ND 23.63 ± 2.73 23.33 ± 4.87
MK801+DOZ(1 mg/kg) 6 24.83 ± 1.72 25.33 ± 1.88 23.00 ± 3.34 25.33 ± 1.68
MK801+RAMH(10 mg/kg) 6 ND ND 21.67 ± 1.74 22.67 ± 2.35
Data are expressed as mean ±SEM of 6 or 8 animals per experimental group. There were no significant differences in total exploratory times among treated groups.
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group with [F(1, 10) = 13.92; P < 0.05]. However, acute systemic
administration with the H3R antagonist DL77 (5 mg/kg, i.p.)
significantly counteracted the induced memory deficits in LTM
when compared to (MK801)-amnesic group with [F(1, 10) =
9.05; P < 0.05] (Figure 4). Moreover, the LTM-enhancing
procognitive effect provided by DL77 (5 mg/kg, i.p.) was reversed
when rats were co-administered with RAMH (10 mg/kg, i.p.,
i.p.) as compared to the (MK801)-amnesic group with [F(1, 10)
= 0.03; p = 0.877]. Notably, the significant LTM enhancing
effect provided with DL77 (5 mg/kg, i.p.) was comparable to
the effects observed by the standard drug DOZ (1 mg/kg, i.p.)
in T2 with [F(1, 10) = 0.08; p = 0.788]. Also and similar to the
results observed in STM, statistical analyses revealed that RAMH
(10 mg/kg, i.p.) alone did not alter LTM in T2 when compared
to the MK801-amnesic group with [F(1, 10) = 0.20; p = 0.67]
(Figure 4).
Effect of DL77 on Rat Anxiety and
Locomotor Activity in EPM Test
Figure 5 shows the observed effects of acute systemic injection
of Saline or H3R antagonist DL77 (5 mg/kg, i.p.) on the anxiety
parameters of rats exposed to the EPM, namely the percentage of
time spent in open arms, the number of entries into open arms,
the percentage entries into open arms, and locomotor activity
expressed as the number of entries into closed arms. Subsequent
post-hoc analyses showed that DL77 (5 mg/kg, i.p.) did not alter
the percentage of time spent exploring the open arms of the maze
during a 5min session when compared to saline-treated group
with [F(1, 10) = 0.19, p = 0.67] (Figure 5A). Moreover, further
analyses of data describing the number and percentage of entries
into the open arms of themaze [F(1, 10) = 0.45, p= 0.52; F(1, 10) =
0.10, p = 0.76, respectively] yielded practically the same results.
As depicted in Figures 5B,C, no significant differences were
obtained between the results in the DL77(5 mg/kg)-treated group
and those observed in the saline-treated group (Figures 5B,C).
Interestingly, the number of closed arm entries following DL77
injection was not significantly changed with [F(1, 10) = 0.12, p
= 0.73], demonstrating that locomotor activity as such was not
modulated following acute systemic administration with the H3R
antagonist DL77 (5 mg/kg, i.p.) (Figure 5D).
DISCUSSION
In the current series of experiments, acute systemic injection
of 2.5, 5, and 10 mg/kg of DL77 ameliorated the memory
deficits induced by MK801 in an inhibitory PAP in rats.
The observed results revealed that DL77 significantly reversed
the memory deficits induced by MK801 (Figure 1). Since
MK801 is a very well-known NMDA receptor antagonist and
NMDA receptors were confirmed with their important role
in both consolidation and retrieval processes, it is likely that
DL77 partially counteracted memory deficits induced with
MK801 through direct interaction and activation of NMDA
receptors by the increased release of central histamine as a
consequence of antagonistic activity of DL77 at histamine H3-
auto-receptors. These latter results are in agreement with earlier
studies in which histamine enhanced NMDA receptor-mediated
neurotransmission in cultured hippocampal cells, indicating that
the interaction between histamine and NMDA receptors might
facilitate the histamine’s capability to counteract MK801-induced
amnesic effect (Vorobjev et al., 1993; Xu et al., 2005; Brabant
et al., 2013; Sadek et al., 2016a). Notably, the procognitive effect
provided by DL77 was dose-dependent, as DL77 at a dose of
5 mg/kg provided significantly higher counteracting effect on
decreased STL time when compared to the lower as well as higher
dose (2.5 and 10mg/kg), respectively, indicating that an optimum
of DL77-provided memory-enhancing effect might have been
reached with a dose of 5 mg/kg, and that off-targets effects could
have been present following acute systemic administration of
DL77 at a dose of 10 mg/kg (Figure 1). Interestingly, the latter
observations for the dose dependency are, also, similar to those
observed in previous preclinical experiments in rodents (Benetti
and Izquierdo, 2013; Benetti et al., 2013; Sadek et al., 2016c).
Moreover, the results observed in regard to dose dependency
strongly support our previous results detected for the effects of
H3R antagonist DL77 (2.5, 5, and 10mg/kg, i.p.) on different
memory stages, namely acquisition, consolidation, and retrieval
(Sadek et al., 2016c). Notably, the observed procognitive effects
for DL77 (5 mg/kg) were comparable to those obtained for
the reference drug DOZ, a procognitive compound available
for memory-enhancing effect, since there is up to date no
reference drug which is targeting H3Rs (Figure 1). Moreover,
the procognitive effects found for DL77 (5 mg/kg) were
completely reversed when animals were pretreated with the CNS
penetrant H3R agonist RAMH, indicating clearly that blockade of
H3Rs substantially contributes in the central neurotransmissions
associated with retrieval processes of tested animals (Figure 2).
Unlike the inhibitory PAP, the NOR paradigm in rodents does
not involve a reward or a punishment, and it takes advantage
of their innate interest for exploring their environment, as it
is established on the natural behavior of rodents. Therefore,
the behavioral reaction of tested animals is not biased by
reinforcement/response interactions of tested rats. Also, the NOR
task is a behavioral paradigm used in animal models to evaluate
aspects related to cognitive performance, e.g., recognition
memory (Jaaro-Peled, 2009; Tseng et al., 2009; Brown et al.,
2013; Callahan et al., 2017). Furthermore, previous preclinical
studies revealed that NOR paradigm can be utilized in cognitive
related experiments due to its sensitivity to both agents capable of
impairing (Ennaceur and Delacour, 1988; Ennaceur and Meliani,
1992a,b) as well as enhancing cognition (Lebrun et al., 2000;
Barak and Weiner, 2011) following acute systemic pre- and/or
post-training administration of the individual agent (King et al.,
2004; de Lima et al., 2005; Pichat et al., 2007). In the current
study, acute systemic post-training injection of DL77 (5 mg/kg,
the most promising dose in PAP test) significantly improved the
exploratory time spent with the novel object compared with the
familiar objects (Figure 3). These observations are in consensus
with previous reports revealing that various H3R antagonists
belonging to the imidazole-based class, e.g., thioperamide and
clobenpropit (Giovannini et al., 1999), and to the non-imidazole-
based class, e.g., pitolisant (Ligneau et al., 2007); GSK189254
(Giannoni et al., 2010); SAR110894 (Griebel et al., 2012), and
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ABT-239 (Provensi et al., 2016) counteracted the memory-
impairing effects of MK801 and scopolamine in NOR tests using
different rodents. In our conducted experiments, DL77 potently
counteracted the LTM-impairing effects induced with MK801,
and these DL77-provided effects were entirely reversed when
rats were co-injected with the H3R agonist RAMH (Figure 3
and Table 1). The latter observations are in agreement with an
earlier study in which RAMH abolished the memory-enhancing
effects provided by H3R antagonist ciproxifan on LTM (Pascoli
et al., 2009). Unlike the results observed for DL77 on LTM, acute
systemic post-training administration of DL77 did not increase
the exploratory time spent with the novel objects in STM when
compared with the familiar objects (Figure 4 and Table 1). The
latter results are in discrepancy with earlier studies in which
H3R antagonist ABT-239 enhanced STM in mice (Provensi et al.,
2016). The discrepancy in the results observed in STM might
be explained with the different species used or the differences
in doses used or in the conduct of experiments. Accordingly,
acute systemic post-training administration of MK801 was
used in the current study to induce amnesia, whereas natural
memory decline as well as presence or absence of histaminergic
neurotransmission were examined in the study conducted by
Provensi et al. (2016). Moreover, the current experimental
findings in NOR obviously point toward profound contribution
of histaminergic H3Rs in neuronal circuits associated with
the DL77-provided procognitive effects in LTM (Figure 4 and
Table 1). The lack of memory-enhancing activity of DL77
in STM is in agreement with previous reports in which no
differences were found in time spent exploring novel object in
wild type (intact brain histamine) and histidine decarboxylase-
knocked out mice (lack of brain histamine) when tested 2 h
post-training (STM), but not when testing 24 h post-training
(LTM), indicating that histaminergic neurotransmission is more
involved the neural circuits which modulate the LTM (Acevedo
et al., 2006, 2007; Provensi et al., 2016). Interestingly, several H3R
antagonists have in earlier preclinical studies been designated
as talented candidates for AD and were suggested to be of
possible novel therapeutics due to their capability to interact
with H3 auto- and hetero-receptors, modulating the synthesis
and release of numerous brain neurotransmitters critical for
cognition, including histamine, dopamine, and acetylcholine
(Brioni et al., 2011; Sadek and Stark, 2015; Sadek et al., 2016b).
The EPM test is considered to be one of the most used animal
tests in neuroscience to assess emotionality-related behaviors,
e.g., anxiety, based on the innate tendency of animals to
avoid open spaces in favor of protected areas, while measuring
percent and/or number of closed arms entries reportedly ensures
that behavior observed in the maze did not simply reflect
drug-induced alterations in locomotor activity (Fernandes and
File, 1996; Hogg, 1996; Alachkar et al., 2017). Notably, DL77
at the dose (5 mg/kg) that exhibited the most encouraging
procognitive effect in PAP and NOR paradigms did not affect
anxiety levels of the adult male Wistar rats (Figures 5A–D).
Also, DL77 administered at the same dose (5 mg/kg) did
not affect the number of closed arm entries, indicating that
DL77 failed to modify locomotion of tested rats, demonstrating
that enhanced memory performance in PAP as well as NOR
is not related to modified emotional responses or altered
spontaneous locomotor activity considered as confounding
factors when assessing memory-enhancing effects in PAP and
NOR (Figure 5D) (McGaugh and Roozendaal, 2009; Charlier
et al., 2013). The latter results are, also, in line with our earlier
results in which acute systemic injection of DL77 (2.5, 5, and
10 mg/kg, i.p.) did not affect spontaneous locomotion of the
same animal species when tested in the open field task (Sadek
et al., 2016c). Therefore, it is unlikely that acute systemic injection
of DL77 (5 mg/kg, i.p.) in the post-training sessions provided
memory-enhancing effects in PAP and NOR paradigms due to a
nonspecific effect rather than improved learning tasks conducted
in the training sessions of both paradigms.
CONCLUSION
The results show that the non-imidazole H3R antagonist DL77
ameliorated cognitive deficits induced by the NMDA receptor
antagonist MK801 in an inhibitory PAP and in NOR paradigms
in rats (Figure 6). Moreover, the results observed in PAP
as well as LTM of NOR indicated that DL77 ameliorated
cognitive deficits through blockade of H3Rs, demonstrating
the therapeutic prospective of H3R antagonists in the future
treatment of neurodegenerative diseases, e.g., AD. However,
additional preclinical experiments in other behavioral test
FIGURE 6 | Schematic representation of proposed ameliorative effects for H3R antagonist DL77 in MK801-induced memory deficit in PAP, NOR, and EPM. PAP,
passive avoidance paradigm; NOR, novel object recognition; EPM, elevated plus maze; , no effect; ↓, ameliorates.
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models and with several rodent species are still warranted to
comprehend the translational validity of the prospective use
of H3R antagonists in future therapy of neurodegenerative
diseases.
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